LAmbre™ Left Atrial Appendage Closure System Post-Market 2-5 Years Follow-Up Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
- Enrollment
- 156
- Locations
- 11
- Primary Endpoint
- The incidence of compound event
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to conduct a continuous telephone follow-up study on subjects who had completed the one-year follow-up of the LAmbre™ left atrial appendage (LAA) system registration trial. The follow-up time was 2 years, 3 years, 4 years and 5 years after left atrial appendage closure operation, to evaluate the long-term safety and effectiveness of LAmbre™ LAA Closure System.
Detailed Description
All subjects who completed 1-year follow-up of the LAmbreTM LAA system registration trial will be conducted 2 years, 3 years, 4 years and 5 years follow-up by the telephone call. During the follow-up, the investigator or his/her designee will use a standardized form to record the occurrence of the subject's safety events and validity endpoint by telephone，and complete the safety and efficacy summary report. The endpoints of the study included compound events, MACCE events, stroke, haemorrhage and other events.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who participated in the LAmbreTM Safety and Efficacy Study and completed the 1-year follow-up.
- •The inclusion criteria of LAmbreTM Safety and Efficacy Study:
- •Age\>=18, CHADS2 score\>=1
- •Patients cannot be treated long-term with Warfarin
- •Eligible for clopidogrel and aspirin
- •Provide written informed consent and agree to comply with the required follow-ups
Exclusion Criteria
- •Exclusion criteria: Patients who did not participate in the LAmbreTM Safety and Efficacy Study or did not complete 1-year follow-up LAmbreTM Safety and Efficacy Study.
- •The exclusion criteria of LAmbreTM Safety and Efficacy Study:
- •Need to take Warfarin
- •Presence of rheumatic, degenerative or congenital valvular heart diseases
- •Early stage or paroxysmal atrial fibrillation
- •Symptomatic patients with carotid artery disease (such as carotid stenosis\>=50%)
- •Heart failure NYHA grade IV
- •Recent 30 days stroke or TIA
- •Presence of active sepsis or endocarditis
- •Cardiac tumours or other malignancy with estimated life expectancy \<2 years
Outcomes
Primary Outcomes
The incidence of compound event
Time Frame: 5 years after the surgery
The compound event including death, systemic embolization, complications related to the device and requiring treatment (cardiac embolism, embolization, stroke, hemorrhage, death).
Secondary Outcomes
- The incidence of MACCE events(2,3,4,5 years postoperative follow-up.)
- The rate of stroke(2,3,4,5 years postoperative follow-up)
- Ischemic stroke rate(2,3,4,5 years postoperative follow-up)
- The event of bleeding(2,3,4,5 years postoperative follow-up)
- Cardiac events(2,3,4,5 years postoperative follow-up)